神经康复研究到达临界点:试验设计、描述与汇总分析中的障碍与机遇
本文为观点性文章,指出神经康复领域非药物干预研究面临普遍样本量小、多中心试验资金有限、干预措施难以标准化和充分描述、缺乏个体患者数据共享激励等障碍,导致无法可靠地进行荟萃分析,并提出改进证据到实施转化路径的实用建议。
要点
- 神经康复非药物干预研究普遍样本量小且多中心试验资金有限。
- 非药物干预难以标准化和充分描述,妨碍可靠荟萃分析。
- 缺乏个体患者数据共享激励,需借鉴新冠疫苗研发协作模式。
核心结论
- 神经康复研究需通过协作、数据共享和多中心试验来克服当前障碍,以改善证据到实施的转化。
研究设计与样本
- 本文为观点性文章,未报告系统检索范围或样本量。
主要发现
- 神经康复领域非药物干预研究普遍存在样本量小的问题,且多中心临床试验资金有限。
- 非药物干预难以标准化和充分描述,且缺乏个体患者数据共享的激励措施。
- 上述障碍导致神经康复非药物临床研究无法进行可靠的荟萃分析。
临床怎么用
- 建议借鉴新冠疫苗研发中的学术、政府和商业协作及数据共享经验,推动神经康复多中心试验和个体患者数据共享。
局限性
- 本文为观点性文章,未提供原始研究数据或系统评价结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The record-breaking pace of COVID-19 vaccine development and implementation depended heavily on collaboration among academic, government, and commercial stakeholders, especially through data-sharing and robust multicenter trials. Collaborative efforts have not been as fruitful in fields such as neurorehabilitation, where non-pharmacological interventions play a much larger role. Barriers to translating scientific advancements into clinical practice in neurorehabilitation include pervasively small study sizes, exacerbated by limited funding for non-pharmacological multicenter clinical trials; difficulty standardizing-and adequately describing-non-pharmacological interventions; and a lack of incentives for individual patient-level data-sharing. These barriers prevent reliable meta-analysis of non-pharmacological clinical studies in neurorehabilitation. This point-of-view will highlight these challenges as well as suggest practical steps that may be taken to improve the neurorehabilitation pipeline between evidence and implementation.
引用
- Savage WM, Harel NY. Reaching a Tipping Point for Neurorehabilitation Research: Obstacles and Opportunities in Trial Design, Description, and Pooled Analysis. Neurorehabil Neural Repair. 2022. PMID: 36113101. doi:10.1177/15459683221124112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。